• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Revvity Announces Financial Results for the Second Quarter of 2025

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    • Revenue of $720 million; 4% reported growth; 3% organic growth
    • GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18
    • Updates full year 2025 guidance

    Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025.

    The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a percentage of revenue, as compared to 12.4% in the same period a year ago.

    Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $1.22 in the same period a year ago. Adjusted operating income was $192 million, as compared to $199 million for the same period a year ago. Adjusted operating profit margin was 26.6% as a percentage of revenue, as compared to 28.8% in the same period a year ago.

    Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

    "The power of Revvity's transformation and consistent execution were evident in our second-quarter performance, enabling us to exceed expectations despite the evolving market environment," said Prahlad Singh, president and chief executive officer of Revvity. "With a strong pipeline of innovation, high-performing teams and disciplined operational focus, we're well-positioned to deliver long-term value creation for our shareholders."

    Financial Overview by Reporting Segment

    Life Sciences

    • Second quarter 2025 revenue was $366 million, as compared to $349 million in the same period a year ago. Revenue increased 5% and organic revenue increased 4% as compared to the same period a year ago.
    • Second quarter 2025 adjusted operating income was $115 million, as compared to $118 million in the same period a year ago. Adjusted operating profit margin was 31.6% as a percentage of revenue, as compared to 33.7% in the same period a year ago.

    Diagnostics

    • Second quarter 2025 revenue was $354 million, as compared to $343 million in the same period a year ago. Revenue increased 3% and organic revenue increased 2% as compared to the same period a year ago.
    • Second quarter 2025 adjusted operating income was $89 million, as compared to $93 million in the same period a year ago. Adjusted operating profit margin was 25.2% as a percentage of revenue, as compared to 27.0% in the same period a year ago.

    Full Year 2025 Guidance

    For the full year 2025, the Company is raising its full year revenue guidance to $2.84-$2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth. The Company is also updating its adjusted EPS guidance to a range of $4.85 to $4.95.

    Guidance for the full year 2025 for adjusted EPS and organic growth is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

    Webcast Information

    The Company will discuss its second quarter 2025 results and its outlook for business trends during a webcast on July 28, 2025, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.revvity.com.

    Use of Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes", "intends", "anticipates", "plans", "expects", "estimates", "projects", "forecasts", "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About Revvity

    At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

    With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

    Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

    Revvity, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED INCOME STATEMENTS

     

     

     

    Three Months Ended

     

    Six Months Ended

    (In thousands, except per share data)

     

    June 29,

    2025

     

    June 30,

    2024

     

    June 29,

    2025

     

    June 30,

    2024

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    720,284

     

     

    $

    691,685

     

     

    $

    1,385,046

     

     

    $

    1,341,605

     

     

     

     

     

     

     

     

     

     

    Cost of revenue

     

     

    327,728

     

     

     

    306,179

     

     

     

    616,944

     

     

     

    601,052

     

    Selling, general and administrative expenses

     

     

    248,526

     

     

     

    251,650

     

     

     

    498,245

     

     

     

    512,221

     

    Research and development expenses

     

     

    53,270

     

     

     

    48,132

     

     

     

    106,867

     

     

     

    98,492

     

     

     

     

     

     

     

     

     

     

    Operating income from continuing operations

     

     

    90,760

     

     

     

    85,724

     

     

     

    162,990

     

     

     

    129,840

     

     

     

     

     

     

     

     

     

     

    Interest income

     

     

    (8,345

    )

     

     

    (20,512

    )

     

     

    (18,426

    )

     

     

    (40,598

    )

    Interest expense

     

     

    22,937

     

     

     

    24,717

     

     

     

    45,901

     

     

     

    49,114

     

    Change in fair value of investments

     

     

    1,955

     

     

     

    (7,777

    )

     

     

    (1,118

    )

     

     

    (6,971

    )

    Other expense, net

     

     

    5,563

     

     

     

    2,634

     

     

     

    15,601

     

     

     

    7,084

     

     

     

     

     

     

     

     

     

     

    Income from continuing operations, before income taxes

     

     

    68,650

     

     

     

    86,662

     

     

     

    121,032

     

     

     

    121,211

     

     

     

     

     

     

     

     

     

     

    Provision for income taxes

     

     

    13,428

     

     

     

    14,056

     

     

     

    24,141

     

     

     

    19,909

     

     

     

     

     

     

     

     

     

     

    Income from continuing operations

     

     

    55,222

     

     

     

    72,606

     

     

     

    96,891

     

     

     

    101,302

     

     

     

     

     

     

     

     

     

     

    Loss from discontinued operations

     

     

    (1,274

    )

     

     

    (17,246

    )

     

     

    (706

    )

     

     

    (19,929

    )

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    53,948

     

     

    $

    55,360

     

     

    $

    96,185

     

     

    $

    81,373

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share:

     

     

     

     

     

     

     

     

    Income from continuing operations

     

    $

    0.47

     

     

    $

    0.59

     

     

    $

    0.82

     

     

    $

    0.82

     

     

     

     

     

     

     

     

     

     

    Loss from discontinued operations

     

     

    (0.01

    )

     

     

    (0.14

    )

     

     

    (0.01

    )

     

     

    (0.16

    )

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    0.46

     

     

    $

    0.45

     

     

    $

    0.81

     

     

    $

    0.66

     

     

     

     

     

     

     

     

     

     

    Weighted average diluted shares of common stock outstanding

     

     

    117,538

     

     

     

    123,477

     

     

     

    118,882

     

     

     

    123,494

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    ABOVE PREPARED IN ACCORDANCE WITH GAAP

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Additional supplemental information(1):

     

     

     

     

     

     

     

     

    (per share, continuing operations)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP EPS from continuing operations

     

    $

    0.47

     

     

    $

    0.59

     

     

    $

    0.82

     

     

    $

    0.82

     

    Amortization of intangible assets

     

     

    0.73

     

     

     

    0.73

     

     

     

    1.41

     

     

     

    1.47

     

    Purchase accounting adjustments

     

     

    0.02

     

     

     

    0.01

     

     

     

    0.02

     

     

     

    0.06

     

    Acquisition and divestiture-related costs

     

     

    0.01

     

     

     

    0.04

     

     

     

    0.03

     

     

     

    0.11

     

    Change in fair value of investments

     

     

    0.02

     

     

     

    (0.06

    )

     

     

    (0.01

    )

     

     

    (0.06

    )

    Significant litigation matters and settlements

     

     

    0.01

     

     

     

    0.05

     

     

     

    0.10

     

     

     

    0.05

     

    Significant environmental matters

     

     

    —

     

     

     

    —

     

     

     

    (0.01

    )

     

     

    —

     

    Mark to market on postretirement benefits

     

     

    —

     

     

     

    —

     

     

     

    0.04

     

     

     

    —

     

    Restructuring and other, net

     

     

    0.10

     

     

     

    0.08

     

     

     

    0.12

     

     

     

    0.18

     

    Tax on above items

     

     

    (0.16

    )

     

     

    (0.21

    )

     

     

    (0.32

    )

     

     

    (0.44

    )

    Adjusted EPS from continuing operations

     

    $

    1.18

     

     

    $

    1.22

     

     

    $

    2.19

     

     

    $

    2.19

     

     

     

     

     

     

     

     

     

     

    (1) amounts may not sum due to rounding

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revvity, Inc. and Subsidiaries

    REVENUE AND OPERATING INCOME (LOSS)

     

     

     

    Three Months Ended

     

    Six Months Ended

    (In thousands, except percentages)

     

    June 29,

    2025

     

    June 30,

    2024

     

    June 29,

    2025

     

    June 30,

    2024

     

     

     

     

     

     

     

     

     

    Revenue and adjusted operating income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    720,284

     

     

    $

    691,685

     

     

    $

    1,385,046

     

     

    $

    1,341,605

     

     

     

     

     

     

     

     

     

     

    Reported operating income from continuing operations

     

    $

    90,760

     

     

    $

    85,724

     

     

    $

    162,990

     

     

    $

    129,840

     

    OP%

     

     

    12.6

    %

     

     

    12.4

    %

     

     

    11.8

    %

     

     

    9.7

    %

    Amortization of intangible assets

     

     

    85,289

     

     

     

    90,620

     

     

     

    167,989

     

     

     

    181,858

     

    Purchase accounting adjustments

     

     

    2,178

     

     

     

    623

     

     

     

    2,001

     

     

     

    7,245

     

    Acquisition and divestiture-related costs

     

     

    1,248

     

     

     

    5,779

     

     

     

    3,789

     

     

     

    17,241

     

    Significant litigation matters and settlements

     

     

    1,124

     

     

     

    6,276

     

     

     

    11,710

     

     

     

    6,276

     

    Significant environmental matters

     

     

    —

     

     

     

    —

     

     

     

    (1,208

    )

     

     

    —

     

    Restructuring and other, net

     

     

    11,203

     

     

     

    9,845

     

     

     

    14,442

     

     

     

    22,201

     

    Adjusted operating income

     

    $

    191,802

     

     

    $

    198,867

     

     

    $

    361,713

     

     

    $

    364,661

     

    OP%

     

     

    26.6

    %

     

     

    28.8

    %

     

     

    26.1

    %

     

     

    27.2

    %

     

     

     

     

     

     

     

     

     

    Segment revenue and segment operating income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

    $

    365,898

     

     

    $

    348,525

     

     

    $

    706,293

     

     

    $

    685,039

     

    Diagnostics

     

     

    354,386

     

     

     

    343,160

     

     

     

    678,753

     

     

     

    656,566

     

    Segment revenue

     

     

    720,284

     

     

     

    691,685

     

     

     

    1,385,046

     

     

     

    1,341,605

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

    $

    115,469

     

     

    $

    117,567

     

     

    $

    221,180

     

     

    $

    218,518

     

     

     

     

    31.6

    %

     

     

    33.7

    %

     

     

    31.3

    %

     

     

    31.9

    %

    Diagnostics

     

     

    89,422

     

     

     

    92,749

     

     

     

    163,437

     

     

     

    168,953

     

     

     

     

    25.2

    %

     

     

    27.0

    %

     

     

    24.1

    %

     

     

    25.7

    %

    Segment operating income

     

     

    204,891

     

     

     

    210,316

     

     

     

    384,617

     

     

     

    387,471

     

     

     

     

     

     

     

     

     

     

    Corporate

     

     

    (13,089

    )

     

     

    (11,449

    )

     

     

    (22,904

    )

     

     

    (22,810

    )

    Adjusted operating income

     

     

    191,802

     

     

     

    198,867

     

     

     

    361,713

     

     

     

    364,661

     

     

     

     

     

     

     

     

     

     

    Amortization of intangible assets

     

     

    (85,289

    )

     

     

    (90,620

    )

     

     

    (167,989

    )

     

     

    (181,858

    )

    Purchase accounting adjustments

     

     

    (2,178

    )

     

     

    (623

    )

     

     

    (2,001

    )

     

     

    (7,245

    )

    Acquisition and divestiture-related costs

     

     

    (1,248

    )

     

     

    (5,779

    )

     

     

    (3,789

    )

     

     

    (17,241

    )

    Significant litigation matters and settlements

     

     

    (1,124

    )

     

     

    (6,276

    )

     

     

    (11,710

    )

     

     

    (6,276

    )

    Significant environmental matters

     

     

    —

     

     

     

    —

     

     

     

    1,208

     

     

     

    —

     

    Restructuring and other, net

     

     

    (11,203

    )

     

     

    (9,845

    )

     

     

    (14,442

    )

     

     

    (22,201

    )

    Reported operating income from continuing operations

     

    $

    90,760

     

     

    $

    85,724

     

     

    $

    162,990

     

     

    $

    129,840

     

     

     

     

     

     

     

     

     

     

    REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

    (In thousands)

    June 29,

    2025

     

    December 29,

    2024

     

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    991,849

     

    $

    1,163,396

    Accounts receivable, net

     

    661,138

     

     

    632,400

    Inventories, net

     

    388,467

     

     

    367,587

    Other current assets

     

    194,729

     

     

    186,225

    Total current assets

     

    2,236,183

     

     

    2,349,608

     

     

     

     

    Property, plant and equipment, net

     

    499,026

     

     

    482,217

    Operating lease right-of-use assets, net

     

    177,168

     

     

    167,716

    Intangible assets, net

     

    2,514,368

     

     

    2,640,921

    Goodwill

     

    6,614,989

     

     

    6,463,619

    Other assets, net

     

    321,055

     

     

    288,397

    Total assets

    $

    12,362,789

     

    $

    12,392,478

     

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt

    $

    230

     

    $

    242

    Accounts payable

     

    178,151

     

     

    167,463

    Accrued expenses and other current liabilities

     

    493,433

     

     

    485,395

    Total current liabilities

     

    671,814

     

     

    653,100

     

     

     

     

    Long-term debt

     

    3,214,324

     

     

    3,150,476

    Long-term liabilities

     

    760,178

     

     

    770,523

    Operating lease liabilities

     

    160,305

     

     

    151,505

    Total liabilities

     

    4,806,621

     

     

    4,725,604

     

     

     

     

    Total stockholders' equity

     

    7,556,168

     

     

    7,666,874

    Total liabilities and stockholders' equity

    $

    12,362,789

     

    $

    12,392,478

     

     

     

     

     

     

     

     

    PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    CONSOLIDATED STATEMENTS OF CASH FLOWS

     

     

    Three Months Ended

     

    Six Months Ended

    (In thousands)

    June 29,

    2025

     

    June 30,

    2024

     

    June 29,

    2025

     

    June 30,

    2024

     

     

     

     

     

     

     

     

    Operating activities:

     

     

     

     

     

     

     

    Net income

    $

    53,948

     

     

    $

    55,360

     

     

    $

    96,185

     

     

    $

    81,373

     

    Loss from discontinued operations, net of income taxes

     

    1,274

     

     

     

    17,246

     

     

     

    706

     

     

     

    19,929

     

    Income from continuing operations

     

    55,222

     

     

     

    72,606

     

     

     

    96,891

     

     

     

    101,302

     

    Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:

     

     

     

     

     

     

     

    Stock-based compensation

     

    10,133

     

     

     

    10,526

     

     

     

    17,864

     

     

     

    22,218

     

    Restructuring and other, net

     

    11,203

     

     

     

    9,845

     

     

     

    14,442

     

     

     

    22,201

     

    Depreciation and amortization

     

    102,778

     

     

     

    107,344

     

     

     

    200,200

     

     

     

    215,146

     

    Change in fair value of contingent consideration

     

    459

     

     

     

    176

     

     

     

    (166

    )

     

     

    6,349

     

    Amortization of deferred debt financing costs and accretion of discounts

     

    1,218

     

     

     

    1,773

     

     

     

    2,320

     

     

     

    3,509

     

    Change in fair value of investments

     

    1,955

     

     

     

    (7,777

    )

     

     

    (1,118

    )

     

     

    (6,971

    )

    Unrealized foreign exchange loss (gain)

     

    206

     

     

     

    (480

    )

     

     

    140

     

     

     

    (857

    )

    Changes in assets and liabilities which provided (used) cash:

     

     

     

     

     

     

     

    Accounts receivable, net

     

    (40,041

    )

     

     

    (8,995

    )

     

     

    (21,901

    )

     

     

    28,194

     

    Inventories, net

     

    11,128

     

     

     

    10,042

     

     

     

    5,642

     

     

     

    17,251

     

    Accounts payable

     

    (5,576

    )

     

     

    (4,747

    )

     

     

    3,278

     

     

     

    (22,974

    )

    Accrued expenses and other

     

    (14,367

    )

     

     

    (7,985

    )

     

     

    (49,177

    )

     

     

    (52,894

    )

    Net cash provided by operating activities of continuing operations

     

    134,318

     

     

     

    182,328

     

     

     

    268,415

     

     

     

    332,474

     

    Net cash used in operating activities of discontinued operations

     

    —

     

     

     

    (23,707

    )

     

     

    (5,942

    )

     

     

    (26,290

    )

    Net cash provided by operating activities

     

    134,318

     

     

     

    158,621

     

     

     

    262,473

     

     

     

    306,184

     

     

     

     

     

     

     

     

     

    Investing activities:

     

     

     

     

     

     

     

    Capital expenditures

     

    (18,868

    )

     

     

    (22,031

    )

     

     

    (34,850

    )

     

     

    (39,875

    )

    Purchases of investments and notes receivables

     

    —

     

     

     

    (4,000

    )

     

     

    —

     

     

     

    (4,337

    )

    Proceeds from disposition of businesses and assets

     

    —

     

     

     

    —

     

     

     

    229

     

     

     

    —

     

    Net cash used in investing activities of continuing operations

     

    (18,868

    )

     

     

    (26,031

    )

     

     

    (34,621

    )

     

     

    (44,212

    )

    Net cash provided by investing activities of discontinued operations

     

    9,375

     

     

     

    147,522

     

     

     

    18,750

     

     

     

    147,522

     

    Net cash (used in) provided by investing activities

     

    (9,493

    )

     

     

    121,491

     

     

     

    (15,871

    )

     

     

    103,310

     

     

     

     

     

     

     

     

     

    Financing Activities:

     

     

     

     

     

     

     

    Payments of debt financing costs

     

    (72

    )

     

     

    —

     

     

     

    (2,474

    )

     

     

    —

     

    Payments on other credit facilities

     

    (53

    )

     

     

    (389

    )

     

     

    (103

    )

     

     

    (11,200

    )

    Payments for acquisition-related contingent consideration

     

    (161

    )

     

     

    —

     

     

     

    (1,978

    )

     

     

    (8,749

    )

    Proceeds from issuance of common stock under stock plans

     

    —

     

     

     

    2,089

     

     

     

    2,632

     

     

     

    6,032

     

    Purchases of common stock

     

    (293,907

    )

     

     

    (19,553

    )

     

     

    (447,501

    )

     

     

    (30,309

    )

    Dividends paid

     

    (8,282

    )

     

     

    (8,642

    )

     

     

    (16,715

    )

     

     

    (17,282

    )

    Net cash used in financing activities of continuing operations

     

    (302,475

    )

     

     

    (26,495

    )

     

     

    (466,139

    )

     

     

    (61,508

    )

     

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

     

    31,953

     

     

     

    (3,654

    )

     

     

    48,075

     

     

     

    (12,931

    )

     

     

     

     

     

     

     

     

    Net (decrease) increase in cash, cash equivalents, and restricted cash

     

    (145,697

    )

     

     

    249,963

     

     

     

    (171,462

    )

     

     

    335,055

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    1,138,687

     

     

     

    999,465

     

     

     

    1,164,452

     

     

     

    914,373

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    992,990

     

     

    $

    1,249,428

     

    $

    992,990

     

     

    $

    1,249,428

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Supplemental disclosure of cash flow information:

     

     

     

     

     

     

     

    Reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total shown in the consolidated statements of cash flows:

     

     

     

     

     

     

     

    Cash and cash equivalents

    $

    991,849

     

     

    $

    1,248,120

     

     

    $

    991,849

     

     

    $

    1,248,120

     

    Restricted cash included in other current assets

     

    1,141

     

     

     

    1,308

     

     

     

    1,141

     

     

     

    1,308

     

    Total cash, cash equivalents and restricted cash

    $

    992,990

     

     

    $

    1,249,428

     

     

    $

    992,990

     

     

    $

    1,249,428

     

     

     

     

     

     

     

     

     

    PREPARED IN ACCORDANCE WITH GAAP

    Revvity, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     

     

     

     

    Continuing Operations

     

     

     

    Three Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    4%

    Less: effect of foreign exchange rates

     

     

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    3%

     

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

     

     

    Three Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    5%

    Less: effect of foreign exchange rates

     

     

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    4%

     

     

     

     

     

     

     

     

     

     

     

    Diagnostics

     

     

     

    Three Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    3%

    Less: effect of foreign exchange rates

     

     

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    2%

     

     

     

     

     

     

     

     

    (1) amounts may not sum due to rounding

     

     

     

    Revvity, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     

     

     

     

    Continuing Operations

     

     

     

    Six Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    3%

    Less: effect of foreign exchange rates

     

     

    0%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    3%

     

     

     

     

     

     

     

     

     

     

     

    Life Sciences

     

     

     

    Six Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    3%

    Less: effect of foreign exchange rates

     

     

    0%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    3%

     

     

     

     

     

     

     

     

     

     

     

    Diagnostics

     

     

     

    Six Months Ended

     

     

     

    June 29, 2025

    Organic revenue growth:

     

     

     

    Revenue growth from continuing operations

     

     

    3%

    Less: effect of foreign exchange rates

     

     

    0%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    4%

     

     

     

     

     

     

     

     

    (1) amounts may not sum due to rounding

     

     

     

    Revvity, Inc. and Subsidiaries

    FY 2025 ORGANIC REVENUE GROWTH FORECAST (1)

     

     

     

     

    Continuing Operations

     

     

     

    Twelve Months Ended

     

     

     

    December 28, 2025

    Organic revenue growth:

     

     

    Projected

    Revenue growth from continuing operations

     

     

    3% - 5%

    Less: effect of foreign exchange rates

     

     

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

     

    0%

    Organic revenue growth from continuing operations

     

     

    2% - 4%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (1) amounts may not sum due to rounding

     

     

     

    Explanation of Non-GAAP Financial Measures

    We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

    We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" or "organic growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

    We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions and asset impairments. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of revenue.

    We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of revenue.

    We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of revenue.

    We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of investments and debt extinguishment costs.

    We use the term "adjusted operating income" to refer to GAAP operating income, excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," and "adjusted operating margin" to refer to adjusted operating income as a percentage of revenue.

    We use the term "free cash flow" to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations ("capital expenditures") plus the proceeds from sales of plant, property and equipment from continuing operations ("capital disposals").

    We use the term "adjusted net income" to refer to GAAP income from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    We use the term "adjusted earnings per share from continuing operations," "adjusted earnings per share," "adjusted EPS," or "adjusted EPS from continuing operations" to refer to GAAP earnings per share from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

    • Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
    • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets, deferred revenue and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
    • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, transformation expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Asset impairments—we incur expenses related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
    • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
    • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
    • Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
    • Changes in value of investments—we exclude the impact of changes in the value of investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

    The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of investments, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, and restructuring and other charges is calculated based on operational results and a blended jurisdictional tax rate, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on a blended jurisdictional tax rate currently in effect to determine our tax provision.

    The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

    Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250728970540/en/

    Investor Relations:

    Steve Willoughby

    [email protected]



    Media Relations:

    Chet Murray

    (781) 462-5126

    [email protected]

    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    SEC Filings

    View All

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    8/5/25 4:10:32 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    7/28/25 7:12:47 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 11-K filed by Revvity Inc.

    11-K - REVVITY, INC. (0000031791) (Filer)

    6/20/25 2:18:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Vohra Tajinder S gifted 12,183 shares and received a gift of 12,183 shares, decreasing direct ownership by 54% to 10,442 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 5:10:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Officer Victor Miriame

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 4:51:41 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Officer Krakowiak Maxwell

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 4:05:05 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity to Present at Upcoming Investor Conferences

    Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor relations & ESG Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will

    8/18/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

    Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research Revvity, Inc. (NYSE:RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitiv

    8/6/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity upgraded by UBS with a new price target

    UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

    5/1/25 7:42:49 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Bernstein with a new price target

    Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

    1/10/25 8:41:17 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity upgraded by BofA Securities with a new price target

    BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

    12/13/24 8:43:02 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

    7/24/25 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, July 28, 2025

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo

    7/7/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials